# OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

> **NCT03527628** · PHASE2 · UNKNOWN · sponsor: **King Abdullah International Medical Research Center** · enrollment: 220 (estimated)

## Conditions studied

- Classical Hodgkin Lymphoma
- Hodgkin Lymphoma (Category)
- Hodgkin Disease
- Hodgkin Lymphoma

## Interventions

- **DRUG:** Adriamycin
- **DRUG:** Cyclophosphamide
- **DRUG:** Vinblastine
- **DRUG:** Dacarbazine
- **DRUG:** Brentuximab Vedotin
- **DRUG:** ABVD

## Key facts

- **NCT ID:** NCT03527628
- **Lead sponsor:** King Abdullah International Medical Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-01
- **Primary completion:** 2021-01-15
- **Final completion:** 2022-01-15
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03527628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03527628, "OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03527628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*